Product

Relatlimab + Nivolumab

Aliases

relatlimab + nivolumab

Name

Relatlimab + Nivolumab

1 clinical trial

2 drugs

1 indication

Indication

Drug

Drug

nivolumab + ipilimumab

Clinical trial

A Phase II Study of Anti-PD1 Monoclonal Antibody (Nivolumab, BMS-936558) Administered in Combination With Anti-LAG3 Monoclonal Antibody (Relatlimab, BMS-986016) in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Status: Active (not recruiting), Estimated PCD: 2027-07-31